Enanta Pharmaceuticals (NASDAQ:ENTA) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a note issued to investors on Monday. The firm presently has a $82.00 price objective on the biotechnology company’s stock. Zacks Investment Research‘s price target would indicate a potential upside of 6.85% from the stock’s current price.
According to Zacks, “Enanta Pharmaceuticals, Inc. is a biotechnology company. It engages in the research and development of molecule drugs for the treatment of infectious diseases such as hepatitis C virus, respiratory tract infections, intravenous and oral treatments. Enanta Pharmaceuticals, Inc. is headquartered in Watertown, Massachusetts. “
Other research analysts have also recently issued reports about the stock. Royal Bank of Canada raised their target price on shares of Enanta Pharmaceuticals to $78.00 and gave the stock a “sector perform” rating in a report on Thursday. BidaskClub cut shares of Enanta Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Saturday. JPMorgan Chase & Co. cut shares of Enanta Pharmaceuticals from an “overweight” rating to a “neutral” rating in a report on Thursday. Finally, TheStreet raised shares of Enanta Pharmaceuticals from a “c+” rating to a “b-” rating in a report on Wednesday, December 13th. Four investment analysts have rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. Enanta Pharmaceuticals currently has a consensus rating of “Hold” and an average target price of $57.40.
Enanta Pharmaceuticals (NASDAQ:ENTA) last announced its earnings results on Monday, November 20th. The biotechnology company reported $1.86 EPS for the quarter, missing the Thomson Reuters’ consensus estimate of $2.13 by ($0.27). Enanta Pharmaceuticals had a return on equity of 13.33% and a net margin of 26.35%. The business had revenue of $75.93 million for the quarter, compared to the consensus estimate of $73.80 million. During the same period in the prior year, the business posted ($0.09) earnings per share. The firm’s revenue for the quarter was up 491.3% compared to the same quarter last year. research analysts expect that Enanta Pharmaceuticals will post 0.86 earnings per share for the current year.
Several institutional investors and hedge funds have recently made changes to their positions in the company. East Coast Asset Management LLC. bought a new position in Enanta Pharmaceuticals in the fourth quarter valued at approximately $218,000. LS Investment Advisors LLC increased its stake in Enanta Pharmaceuticals by 56.8% in the fourth quarter. LS Investment Advisors LLC now owns 3,714 shares of the biotechnology company’s stock valued at $218,000 after acquiring an additional 1,345 shares during the last quarter. Campbell & CO Investment Adviser LLC bought a new position in Enanta Pharmaceuticals in the third quarter valued at approximately $220,000. Hartland & Co. LLC bought a new position in Enanta Pharmaceuticals in the third quarter valued at approximately $237,000. Finally, UBS Asset Management Americas Inc. bought a new position in Enanta Pharmaceuticals in the fourth quarter valued at approximately $241,000. 68.04% of the stock is currently owned by institutional investors.
ILLEGAL ACTIVITY NOTICE: “Enanta Pharmaceuticals (ENTA) Upgraded to Buy at Zacks Investment Research” was first posted by American Banking News and is owned by of American Banking News. If you are reading this piece of content on another publication, it was illegally stolen and reposted in violation of US and international copyright and trademark legislation. The original version of this piece of content can be viewed at https://www.americanbankingnews.com/2018/02/12/enanta-pharmaceuticals-enta-upgraded-to-buy-at-zacks-investment-research.html.
About Enanta Pharmaceuticals
Enanta Pharmaceuticals, Inc is a research and development-focused biotechnology company. The Company uses chemistry-driven approach and drug discovery solutions to create small molecule drugs for the treatment of viral infections and liver diseases. Its research and development programs are focused on three disease targets: non-alcoholic steatohepatitis (NASH)/ primary biliary cholangitis (PBC), respiratory syncytial virus (RSV) and hepatitis B virus (HBV).
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Enanta Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enanta Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.